iShares Genomics Immunology and Healthcare ETF IDNA ETF Analysis

| Medalist Rating as of | See iShares Investment Hub

Morningstar’s Analysis IDNA

Will IDNA outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

iShares Genomics Immnlgy & Hlthcr ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Sponsor Center